Get the Stockscreener App
1.24
8.82%
-0.12
Codexis Inc stock is traded at $1.24, with a volume of 979.57K.
It is down -8.82% in the last 24 hours and down -7.46% over the past month.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$1.36
Open:
$1.36
24h Volume:
979.57K
Relative Volume:
1.17
Market Cap:
$135.79M
Revenue:
$78.09M
Net Income/Loss:
$-31.99M
P/E Ratio:
-3.416
EPS:
-0.363
Net Cash Flow:
$-22.12M
1W Performance:
-12.06%
1M Performance:
-7.46%
6M Performance:
-51.18%
1Y Performance:
-53.03%
1-Day Range:
$1.22
$1.36
1-Week Range:
$1.22
$1.43
52-Week Range:
$0.9583
$2.98
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.24 | 135.79M | 78.09M | -31.99M | -22.12M | -0.363 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Codexis Inc (4QK.DU) interactive stock chart - Yahoo Finance Australia
Codexis CFO Georgia Erbez sells $8,619 of common stock - Investing.com
President and CEO Alison Moore sells $8,619 in Codexis stock - Investing.com
President and CEO Alison Moore sells $8,619 in Codexis stock By Investing.com - Investing.com South Africa
Form 4 Codexis Inc: Alison Moore (Director, President and CEO) For: 12 October - Investing.com Nigeria
An $8.62K share sale proposed by Codexis (CDXS) officer Georgia Erbez involves a vested stock grant. - Stock Titan
Officer Alison Moore proposes selling 6,335 Codexis (Nasdaq: CDXS) shares. - Stock Titan
Codexis (CDXS) Partners on Stereo-Defined siRNA Fragment Synthes - gurufocus.com
Codexis partners with siRNA innovator on enzyme synthesis By Investing.com - Investing.com Canada
Codexis partners with siRNA innovator on enzyme synthesis By Investing.com - Investing.com Nigeria
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Yahoo Finance Australia
Codexis Enters into an Agreement with Pioneering siRNA Drug - GlobeNewswire
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA - Yahoo Finance
Codexis (NasdaqGS:CDXS) Stock Forecast & Analyst Predictions - Simply Wall Street
Codexis at Cantor conference: enzymatic RNA manufacturing gains ground By Investing.com - Investing.com Canada
Codexis (CDXS) Q2 2026 Earnings: Loss Narrower Than Expected, Shares Decline 2.03%Revenue Per Share - vinanet.vn
Codexis (CDXS) Slides 3.61% to $1.60: Key Support Levels Under ScrutinyBollinger Expansion - vinanet.vn
Codexis (CDXS) Slides 3.61% to $1.60: Key Support Levels Under ScrutinyIV Rank - siam.in
Codexis to Participate in Cantor Global Healthcare Conference 2026 - GlobeNewswire
Codexis Management Will Participate in a Sept. 10 Fireside Chat - Stock Titan
Codexis to Participate in Cantor Global Healthcare Conference 2026 - Yahoo Finance
Codexis (CDXS) Financial Results: The Available Earnings Metric Delivers a Beat in the Latest Reading; Session Move - vinanet.vn
Codexis (CDXS) Financial Results: The Available Earnings Metric Delivers a Beat in the Latest Reading; Session Move - dars.gov.et
Codexis (CDXS) Q2 2026 Earnings Call Transcript - The Globe and Mail
CDXS Maintained by Piper Sandler -- Price Target Lowered to $8.0 - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ - GuruFocus
Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen - MarketBeat
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares - Stock Titan
Codexis earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside - TradingView
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... - finance.yahoo.com
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocataly - GuruFocus
Codexis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CDXS Looks 40.1% Undervalued on GF Value™ Amidst Challenging Fun - GuruFocus
Codexis narrows Q2 loss, raises $25M to fund GMP expansion - scanx.trade
Codexis Affirms FY26 Sales Guidance Range Amid Stable Outlook - scanx.trade
Transcript : Codexis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Codexis (NASDAQ:CDXS) Issues Earnings Results - MarketBeat
Codexis Q2 Earnings Call Highlights - MarketBeat
Codexis Q2 Earnings Call Highlights - Yahoo Finance
CDXS: Q2 2026 saw revenue of $14.9M, margin gains, new financing, and major ECO Synthesis advances - tradingview.com
Earnings call transcript: Codexis beats Q2 2026 estimates as shares rise after hours - Investing.com
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
How Did Codexis Inc (CDXS) Perform in Q2? EPS at -0.14, Revenue Beats Estimates; GF Score: 49/100 - GuruFocus
Codexis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CODEXIS ($CDXS) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Codexis: Q2 Earnings Snapshot - marketscreener.com
Codexis: Q2 Earnings Snapshot - 10TV
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Codexis Inc Stock (CDXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOORE ALISON | Officer |
Oct 12 '26 |
Proposed Sale |
1.36 |
6,335 |
8,619 |
0 |
| Erbez Georgia | Officer |
Oct 12 '26 |
Proposed Sale |
1.36 |
6,335 |
8,619 |
0 |
| MOORE ALISON | President and CEO |
Oct 12 '26 |
Sale |
1.36 |
6,335 |
8,619 |
244,171 |
| De Vre Raymond | Director |
Jun 11 '26 |
Sale |
2.37 |
2,605 |
6,174 |
84,811 |
| Lutz Stefan | Chief Scientific Officer |
Feb 24 '26 |
Sale |
1.13 |
5,862 |
6,641 |
130,421 |
| Lutz Stefan | Officer |
Feb 24 '26 |
Proposed Sale |
1.17 |
5,280 |
6,178 |
0 |
| Lutz Stefan | Officer |
Feb 06 '26 |
Proposed Sale |
1.27 |
2,460 |
3,124 |
0 |
| Norrett Kevin | Officer |
Feb 06 '26 |
Proposed Sale |
1.27 |
3,291 |
4,180 |
0 |
| MOORE ALISON | President and CEO |
Feb 06 '26 |
Sale |
1.31 |
3,826 |
5,001 |
250,506 |
| Erbez Georgia | See Remarks |
Feb 06 '26 |
Sale |
1.31 |
3,826 |
5,001 |
66,810 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):